Gene Therapy for Rare Diseases Dominates Approved Products and Clinical Trials
A recent cross-sectional registry analysis has revealed that rare disorders account for 80% of approved gene therapy products and over 44% of all registered gene therapy clinical trials. The study, which analyzed 1,464 registered clinical investigations, identified 646 studies specifically targeting rare conditions, spanning 175 distinct rare diseases. The findings indicate a substantial and sustained growth in rare disease research over the past decade, with annual trial initiations more than tripling from 21 in 2015 to 73 in 2024. The research team integrated data from multiple public registries, including the United States Food and Drug Administration (FDA), Orphanet, and ClinicalTrials.gov. Of the 30 FDA-approved gene therapy products, 24 (80%) carried at least one rare disease indication, covering 16 distinct rare diseases. Despite this progress, early-phase trials still constitute nearly two-thirds of the investigational pipeline, and there is a significant geographic concentration of trials, with th...
